In oropharyngeal cancer, HPV status impacts distant mets risk
(HealthDay)—In patients with oropharyngeal cancer (OPC), human papillomavirus (HPV) status and T and N staging categories affect the rate of distant control (DC) and may help identify candidates for treatment deintensification strategies, according to research published online Jan. 7 in the Journal of Clinical Oncology.
Brian O'Sullivan, M.D., of the Princess Margaret Hospital/University of Toronto, and colleagues conducted a study involving 899 patients with OPC to identify patients with HPV-associated OPC who would be suitable for treatment deintensification strategies, that omit chemotherapy, based on their having a low risk of distant metastasis (DM).
Of the cohort, HPV status was ascertained for 505 patients, of which 382 were HPV-positive and 123 HPV-negative. During a median follow-up of 3.9 years, the researchers found that HPV-positive patients had significantly higher local and regional control but similar DC, compared with HPV-negative patients. HPV negativity, N2b-N3, T4, and radiation therapy alone were predictive of lower recurrence-free survival. HPV-positive patients were classified according to whether their risk of DM was low (T1-3N0-2c; DC, 93 percent) or high (N3 or T4; DC, 76 percent). HPV-negative patients were also classified into low (T1-2N0-2c; DC, 93 percent) and high DM risk (T3-4N3; DC, 72 percent) groups. In the HPV-positive, low-risk N2c subset, the DC rate was lower with treatment by radiotherapy alone (73 versus 92 percent for chemoradiotherapy).
"The prognostic value of T and N categories on DM risk seems to be different for HPV-positive versus HPV-negative patients," the authors write. "A deintensification philosophy might be most optimally deployed in such subgroups with the least likelihood of DM."
Full Text (subscription or payment may be required)
Copyright © 2013 HealthDay. All rights reserved.